Beta Blocker Use Tied to Reductions in Violence
Seena Fazel of the University of Oxford, UK, and colleagues at the Karolinska Institute in Sweden compared the medicated and non-medicated periods of over 1.4 million beta blocker users.
Diagnosis & Disease Information
Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
MPR Weekly Dose Podcast #137
USPSTF recommendations on estrogen and progesterone; semaglutide assessed in obese teenagers; efficacy and safety data released for investigational maternal RSV vaccine; updates to Clozapine REMS; FDA panel votes on investigational CNS/leptomeningeal metastasis treatment.
Issues With Patient Access to Clozapine Prompt REMS Update
The FDA does not intend to object if inpatient pharmacies dispense a days’ supply of clozapine that aligns with the patient’s monitoring frequency upon discharge from the facility.
Haloperidol Not Beneficial for ICU Patients With Delirium
No improvement seen in number of days alive and out of the hospital at 90 days for haloperidol versus placebo
Effectiveness of Antipsychotics Dips for Women After Age 45 Years
Findings compared with both younger women and similarly aged men
September 2022 Recap: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in September 2022 for investigational products in development.
Aripiprazole 2-Month Under Review for Schizophrenia, Bipolar I Disorder
The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot.
August 2022 Recap: Drug Pipeline Update
Stay up-to-date on the latest drugs in development.
